{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:22:46Z","timestamp":1794590566365,"version":"4.9.1"},"reference-count":21,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Evidence supporting intravenous\u2010to\u2010oral (IV\u2010to\u2010PO) antibiotic deescalation for uncomplicated streptococcal bloodstream infections (BSIs) are limited. The objective of this study was to compare clinical outcomes of patients treated with IV\u2010only versus IV\u2010to\u2010PO antibiotic therapy for uncomplicated streptococcal BSIs. This was a single\u2010center, retrospective study of patients aged \u226518 years who received treatment for uncomplicated streptococcal BSIs from January 2017 to December 2019. Patients were excluded if they had a polymicrobial BSI, endocarditis, osteomyelitis, septic arthritis, or received antibiotic therapy for &gt;14 days. The primary outcome was clinical failure, defined as persistent bacteremia, recurrence of bacteremia, or mortality at 30 days. Secondary outcomes included length of hospital stay, all\u2010cause readmissions, development of <jats:italic>Clostridioides difficile<\/jats:italic> infection, and adverse antibiotic reactions. There were 98 patients who met the inclusion criteria: 51 patients in the IV\u2010to\u2010PO therapy group and 47 patients who received IV\u2010only antibiotics. <jats:italic>Streptococcus pneumoniae<\/jats:italic> and beta\u2010hemolytic streptococci were the most common pathogens. Patients received an average of 4.4 days of IV antibiotics before being stepped down to an oral agent. Hospital length of stay (6.3 vs 12.6 days; <jats:italic>P<\/jats:italic> &lt; .001) and total antibiotic duration of therapy (11.8 vs 13.9 days; <jats:italic>P<\/jats:italic> = .002) were significantly shorter in patients receiving IV\u2010to\u2010PO therapy. There were no clinical failures observed in patients who received IV\u2010to\u2010PO antibiotic therapy. IV\u2010to\u2010PO step\u2010down therapy for uncomplicated streptococcal BSIs was not associated with worse clinical outcomes compared to patients receiving IV\u2010only antibiotic therapy.<\/jats:p>","DOI":"10.1002\/jcph.2097","type":"journal-article","created":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T12:08:46Z","timestamp":1654430926000},"page":"1372-1378","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A Retrospective Analysis of Intravenous vs Oral Antibiotic Step\u2010Down Therapy for the Treatment of Uncomplicated Streptococcal Bloodstream Infections"],"prefix":"10.1002","volume":"62","author":[{"given":"Gerardo P.","family":"Ramos\u2010Otero","sequence":"first","affiliation":[{"name":"Nova Southeastern University College of Pharmacy  Fort Lauderdale Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-5217","authenticated-orcid":false,"given":"Preeyaporn","family":"Sarangarm","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of New Mexico Hospital  Albuquerque New Mexico USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1367-6048","authenticated-orcid":false,"given":"Carla","family":"Walraven","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of New Mexico Hospital  Albuquerque New Mexico USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12195"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2018.03.005"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.10.031"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00355-19"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2008.10.004"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603000605"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2006.07.009"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.04.010"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710926"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.12.007"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.6.848"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy210.838"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01515-20"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.04.003"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808312"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61233-2"},{"key":"e_1_2_9_18_1","first-page":"1","article-title":"Effectiveness of oral antibiotics for definitive therapy of non\u2010Staphylococcal Gram\u2010positive bacterial bloodstream infections","volume":"6","author":"Quinn NJ","year":"2019","journal-title":"Ther Adv Infectious Dis."},{"key":"e_1_2_9_19_1","volume-title":"CLSI supplement M100\u2010ED32: 2022 performance standards for antimicrobial susceptibility testing","author":"Lewis JS","year":"2022"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1594774"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.046723"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2097","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.2097","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:34:39Z","timestamp":1692664479000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/jcph.2097"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2097","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"2022-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}